205.44
-3.14(-1.51%)
Currency In USD
| Previous Close | 208.58 |
| Open | 209.46 |
| Day High | 212 |
| Day Low | 204.77 |
| 52-Week High | 223.19 |
| 52-Week Low | 118.03 |
| Volume | 468,389 |
| Average Volume | 486,307 |
| Market Cap | 12.38B |
| PE | -46.06 |
| EPS | -4.46 |
| Moving Average 50 Days | 204.94 |
| Moving Average 200 Days | 179.31 |
| Change | -3.14 |
If you invested $1000 in Ascendis Pharma A/S (ASND) 10 years ago, it would be worth $12,338.74 as of December 06, 2025 at a share price of $205.44. Whereas If you bought $1000 worth of Ascendis Pharma A/S (ASND) shares 5 years ago, it would be worth $1,195.04 as of December 06, 2025 at a share price of $205.44.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia
GlobeNewswire Inc.
Nov 25, 2025 11:15 PM GMT
– Prescription Drug User Fee Act (PDUFA) goal date extended by three months to February 28, 2026 COPENHAGEN, Denmark, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food & Drug Administration (FD
Results of Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) in Children with Achondroplasia Published in JAMA Pediatrics
GlobeNewswire Inc.
Nov 17, 2025 9:01 PM GMT
COPENHAGEN, Denmark, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that pivotal Week 52 results from its randomized double-blind, placebo-controlled ApproaCH Trial of investigational once-weekly TransCon® CNP
New Pooled 3-Year Analysis Confirms Sustained, Clinically Meaningful Improvements in Renal Function for TransCon® PTH (Palopegteriparatide)-Treated Adults with Hypoparathyroidism
GlobeNewswire Inc.
Nov 07, 2025 1:30 PM GMT
COPENHAGEN, Denmark, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that a new pooled analysis showed sustained and clinically meaningful improvements in renal function in adults with hypoparathyroidism treated